Written by Klarity Editorial Team
Published: May 8, 2026

If you’re a psychiatrist or PMHNP wondering whether you can manage anxiety patients entirely through telehealth — including prescribing benzodiazepines and other controlled substances — the short answer is yes, you can. But the real question is: what are the rules, and how do they affect your practice?
Let’s cut through the noise. Federal telehealth flexibilities that started during COVID have been extended through December 2026, meaning you can prescribe controlled anxiety medications (including Schedule IV benzos like alprazolam) via video visits without requiring an initial in-person encounter. State laws add another layer — some states have specific carve-outs for psychiatric prescribing, while others impose collaboration requirements on nurse practitioners that don’t apply to physicians.
This guide walks through what psychiatrists and PMHNPs can actually do when treating anxiety via telehealth, how scope of practice varies by state, what reimbursement looks like for medication management, and how to navigate the regulatory landscape without getting tripped up.
The Ryan Haight Act normally requires an in-person medical evaluation before prescribing controlled substances. But that requirement has been on pause since March 2020. The DEA and HHS have repeatedly extended these COVID-era flexibilities, most recently through December 2026, to prevent millions of patients from losing access to telehealth prescribing for ADHD, anxiety, and other conditions.
Here’s what this means for you:
What’s coming: The DEA is expected to finalize permanent telemedicine prescribing regulations by late 2026. These will likely include some form of special telemedicine registration or modified exam requirements, but the goal is to avoid a ‘telemedicine cliff’ where access suddenly disappears.
Bottom line for psychiatrists: You have wide latitude to treat anxiety patients remotely right now. Just stay alert to DEA announcements in Q4 2026 about the permanent rules that will replace these temporary flexibilities.
Federal rules set the floor, but states can add requirements. Here’s what matters for the major markets:
Florida explicitly permits teleprescribing of Schedule II controlled substances for psychiatric disorders — meaning even stimulants for treatment-resistant anxiety are allowed via telemedicine. For Schedule IV benzos (the more common anxiety meds), there’s no state restriction at all.
Key requirement: You must check Florida’s PDMP (E-FORCSE) before prescribing any controlled substance, just like in-person care.
Out-of-state caveat: Florida allows out-of-state providers to register for a telehealth-only credential, but those with just the telehealth registration cannot prescribe controlled substances remotely. You need a full Florida license with a Florida DEA registration to prescribe anxiety meds to Florida patients.
Texas doesn’t prohibit telehealth prescribing of controlled substances for psychiatric treatment, but it does ban using controlled drugs to treat chronic pain via telemedicine. That ban doesn’t apply to anxiety or other mental health conditions.
Requirements:
Texas is also part of the Interstate Medical Licensure Compact (IMLC), which streamlines multi-state licensing for physicians wanting to practice telehealth across state lines.
No unique state restrictions on telehealth prescribing beyond federal law. You can prescribe Schedule II–V medications via video consultation as long as you conduct an appropriate exam and document the encounter.
Payment parity: California’s AB 744 requires private insurers to reimburse telehealth psychiatric services at the same rate as in-person visits — making telepsychiatry financially viable.
Multi-state note: California is not in the IMLC, so out-of-state psychiatrists need a full California license to treat California patients remotely.
New York integrates telehealth into standard practice with no special prescribing limitations for controlled substances. You can manage anxiety entirely via telemedicine, including prescribing benzos and stimulants.
PDMP requirement: New York has one of the strictest PDMP mandates — you must check the iSTOP database for every controlled substance prescription, every time. No exceptions.
Medicare consideration: Federal rules temporarily waived the requirement for Medicare patients to have periodic in-person visits for tele-mental health services. That waiver has been extended multiple times and is currently in effect through at least late 2025. Verify current Medicare policy, but for now you can treat Medicare anxiety patients via telehealth without mandatory in-person check-ins.
Neither state has telehealth-specific restrictions on controlled substance prescribing for mental health. Both require PDMP checks (Pennsylvania’s ABC-MAP and Illinois’ PMP), but otherwise you follow the same standards of care as in-person practice.
Pennsylvania note: The state doesn’t have a comprehensive telehealth statute, but providers follow federal rules and professional board guidance. Many insurers voluntarily reimburse telepsychiatry at parity.
Illinois note: Strong telehealth parity law (2021) requires insurers to cover tele-mental health equivalently to in-person care.
This is where things get more complicated. Psychiatrists (MD/DO) can prescribe any anxiety medication independently in all 50 states. Psychiatric Mental Health Nurse Practitioners (PMHNPs) face varying levels of state-mandated physician oversight depending on where they practice.
In states like New York, Oregon, Washington, and Arizona, PMHNPs can evaluate, diagnose, and prescribe anxiety medications (including benzodiazepines) completely independently — no physician collaboration required.
New York’s 2022 change: New York removed its collaborative agreement requirement in April 2022, making it a full practice authority state. A New York PMHNP now has essentially the same prescribing authority as a psychiatrist for anxiety treatment.
States like Texas, Florida, Pennsylvania, and (partially) California require PMHNPs to maintain a formal relationship with a physician to prescribe.
Texas:
Florida:
California:
Pennsylvania:
Illinois:
These collaboration requirements aren’t just regulatory hurdles — they have real cost implications. Some physicians charge PMHNPs a fee for collaboration agreements (sometimes $500–2,000/month). There may also be geographic restrictions (in Texas, the collaborating physician generally must be within 75 miles).
For telehealth platforms, this means NPs in restricted states need local physician partners to operate, while psychiatrists don’t. That’s one reason platforms might preferentially recruit psychiatrists in certain markets, or why they structure NP compensation differently to account for collaboration costs.
Understanding reimbursement matters because it affects your income potential on any telehealth platform. Here’s what psychiatrists and PMHNPs can expect for anxiety medication management in 2026:
Medicare is the benchmark most insurers follow:
Telehealth parity: Medicare pays the same rate for telehealth psychiatric visits as in-person through at least December 2024, and likely through September 2025 based on recent extensions.
Medicaid pays significantly less — roughly 50-60% of Medicare:
The lower rates are offset by high patient volume in many markets. For telehealth platforms serving Medicaid populations, the business model depends on efficiency and scale.
Private insurers typically pay 100-150% of Medicare rates:
Many states have telehealth parity laws requiring commercial insurers to reimburse tele-mental health at the same rate as in-person care (California, Illinois, New York all have this). Texas doesn’t mandate parity, but many insurers pay equivalently anyway.
Here’s a critical difference: Medicare reimburses PMHNPs at 85% of the physician fee schedule when the NP bills under their own NPI. So if a psychiatrist gets $100 for a visit, an NP gets $85 for the same service.
Some practices use ‘incident to’ billing to get 100% reimbursement for NP services (billing under the physician’s NPI), but this generally doesn’t work in psychiatry or telehealth because each visit is a direct provider-patient encounter that doesn’t meet ‘incident to’ criteria.
For telehealth platforms: This means psychiatrist visits generate slightly more revenue per encounter, though NP salaries are typically lower, which can balance out the economics.
Since 2021, E/M coding is based on time or medical decision-making (MDM). For anxiety follow-ups:
Proper documentation is critical. Note the patient’s symptoms, medication efficacy, side effects reviewed, and treatment plan changes. For telehealth visits, document that the encounter was via telehealth and note patient consent.
Let’s address the elephant in the room: patient acquisition cost.
If you’re considering solo practice or DIY marketing versus joining a telehealth platform, you need to understand the real economics. Here’s what providers often don’t calculate:
SEO takes 6-12 months of consistent investment before generating meaningful patient flow. Most solo providers don’t have the expertise or patience for this.
Google Ads for mental health keywords run $15-40+ per click, and most clicks don’t convert to booked patients. A realistic cost per booked patient through PPC is $200-400+ when you factor in:
Directory listings (Psychology Today, Zocdoc) charge monthly fees AND you compete with hundreds of other providers on the same page. Zocdoc charges per booking ($35-100+) but total monthly cost including subscription adds up. Psychology Today is a $30/month subscription but doesn’t guarantee patient flow.
When you add it all up: Most providers who successfully build a patient base through DIY marketing spend $3,000-5,000/month on marketing channels, with uncertain results, especially in the first 6-12 months.
Telehealth platforms like Klarity use a pay-per-appointment model — you pay a standard listing fee per new patient lead, and that’s it.
The value proposition:
Frame it this way: Instead of gambling $3,000-5,000/month on marketing with uncertain ROI, you pay only when a qualified patient books with you. That’s guaranteed ROI versus rolling the dice on marketing channels.
DIY marketing can eventually be cost-effective IF you have the budget, expertise, and patience — but for most providers, especially those starting out or scaling, a platform that handles patient acquisition removes the risk entirely.
Yes, under current federal rules extended through December 2026. You can initiate Schedule IV anxiolytics (Xanax, Ativan, Klonopin) via video consultation without requiring an initial in-person visit. State PDMP checks still apply.
It depends on the state. In full practice authority states (New York, Arizona, Oregon, Washington), PMHNPs can prescribe anxiety medications including controlled substances completely independently. In restricted states (Texas, Florida, Pennsylvania), they need a physician collaboration agreement.
Yes. You need a DEA registration in each state where you’re licensed and prescribing controlled substances, even if you’re only seeing patients via telehealth. The registration is tied to a physical address in that state (typically your practice location or home address if practicing remotely).
Medicaid pays roughly 50-60% of Medicare rates. A medication follow-up (99213) that pays ~$95 under Medicare might pay ~$40-50 under Medicaid. The lower per-visit payment is often offset by higher patient volume.
Only if you’re fully licensed in that state. You must hold an active medical license and DEA registration in the state where the patient is located when receiving care. Some states participate in compacts (like the IMLC for physicians) that streamline multi-state licensing.
Telehealth parity laws (in states like California, Illinois, New York) require insurers to reimburse tele-mental health services at the same rate as in-person care. This prevents insurers from paying less just because the visit was virtual, making telepsychiatry financially viable.
The DEA is expected to finalize permanent telemedicine prescribing regulations by late 2026. These will likely include some form of special telemedicine registration or modified exam requirements, but the goal is to preserve access while adding appropriate safeguards. Stay tuned to DEA announcements in Q4 2026.
The psychiatrist shortage is real — states like Texas have one psychiatrist for every 8,966 residents, and Florida’s ratio is similar at 1:8,577. Anxiety disorders are among the most common mental health conditions, and demand for medication management is high nationwide.
Telehealth platforms solve three core problems:
Patient acquisition: Platforms handle marketing and match pre-qualified patients to your availability. No need to spend thousands per month on SEO or Google Ads hoping for patient flow.
Infrastructure: Built-in telehealth technology, EHR integration, and billing support. You don’t need to contract with multiple software vendors or hire admin staff to manage claims.
Flexibility: Control your schedule and practice across state lines (with appropriate licensure). See patients from multiple states without opening physical offices in each location.
For anxiety specialists, joining a telepsychiatry platform offers access to broader patient populations, streamlined reimbursement, and flexible practice — all within the bounds of state and federal regulations.
If you’re a psychiatrist or PMHNP looking to expand your anxiety practice via telehealth, the regulatory environment in 2026 is more permissive than ever. The federal rules are clear, state laws are increasingly favorable (especially for PMHNPs gaining independence), and reimbursement supports virtual care.
The real question isn’t whether you can prescribe anxiety medications via telehealth — it’s whether you’re ready to leverage these tools to reach patients who need you.
Ready to explore telehealth opportunities? Consider joining Klarity Health’s provider network to connect with anxiety patients seeking medication management, without the upfront marketing costs and infrastructure headaches of solo practice.
The following sources were consulted to provide up-to-date information (all sources verified for currentness as of February 26, 2026):
HHS Press Release – ‘HHS & DEA Extend Telemedicine Flexibilities through 2026’ (hhs.gov) – Official government source on federal telehealth prescribing policy, Jan 2, 2026.
Florida Statutes §464.012 and §456.47 – Nurse Practice Act & Telehealth (flsenate.gov) – State law text defining NP scope and telehealth rules in Florida, 2024 Statutes.
California Board of Registered Nursing – AB 890 Implementation FAQs (rn.ca.gov) – State regulatory guidance on new NP independent practice categories, updated 2024.
NPNY announcement – ‘NP Modernization Act Passes in NY’ (npny.enpnetwork.com) – NY NP association outlining changes in law, April 9, 2022.
NursePractitionerLicense.com – Illinois NP Licensure & Limitations – Informational site citing state law for Illinois NP practice authority, updated Feb 12, 2024.
Find the right provider for your needs — select your state to find expert care near you.